Drugs / MW02
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT05297292 | May 2021 → May 2023 | wet macular degeneration | Mabwell (Shanghai) Bioscience Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MW02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05297292 ↗ |
| Action | Inhibit | “anti-VEGF” NCT05297292 ↗ |
| Modality | Monoclonal antibody | “recombinant anti-VEGF humanized monoclonal antibody injection” NCT05297292 ↗ |
| Route | Intravitreal | “Intravitreal injection was used, and the dose was 1.0mg.” NCT05297292 ↗ |